Compare Cardinal Health Inc (CAH) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs JPMorgan Chase & Co — how do they compare? Cardinal Health Inc trades at $228.57 (market cap $53.89B), while JPMorgan Chase & Co trades at $349.06 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 16.9× Cardinal Health Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.75%). Which is the better fit depends on your goals.
| CAH | JPM | |
|---|---|---|
Market Cap | $53.89B | $911.47B |
Sector | Health | Financials |
52-Week High | $239.71 | $342.89 |
52-Week Low | $146.04 | $282.84 |
Enterprise Value | $58.87B | — |
Dividend Yield | 0.89% | 1.75% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
JPMorgan Chase (JPM) trades at $347.74, up 3.95% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The stock shows robust fundamentals including a 31.61% net income margin and 17.03% ROE, though cash flow trends indicate significant financing activity. Market sentiment is positive amid upcoming bank earnings and macroeconomic commentary from CEO Jamie Dimon.
The outlook for JPM remains favorable with a consensus price target of $377.75, suggesting upside potential. Key opportunities include earnings momentum and sector leadership, while risks involve geopolitical tensions, cybersecurity threats, and volatile cash flows. Institutional holdings reflect confidence, but investors should monitor interest rate impacts and economic guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
